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Abstract: Camptodactyly-arthropathy-coxa vara-pericarditis (CACP) syndrome leads to diarthrodial
joint arthropathy and is caused by the absence of lubricin (proteoglycan 4—PRG4), a surface-active
mucinous glycoprotein responsible for lubricating articular cartilage. In this study, mice lacking the
orthologous gene Prg4 served as a model that recapitulates the destructive arthrosis that involves
biofouling of cartilage by serum proteins in lieu of Prg4. This study hypothesized that Prg4-deficient
mice would demonstrate a quadruped gait change and decreased markers of mitochondrial dyscrasia,
following intra-articular injection of both hindlimbs with recombinant human PRG4 (rhPRG4).
Prg4−/− (N = 44) mice of both sexes were injected with rhPRG4 and gait alterations were studied
at post-injection day 3 and 6, before joints were harvested for immunohistochemistry for caspase-3
activation. Increased stance and propulsion was shown at 3 days post-injection in male mice. There
were significantly fewer caspase-3-positive chondrocytes in tibiofemoral cartilage from rhPRG4injected mice. The mitochondrial gene Mt-tn, and myosin heavy (Myh7) and light chains (Myl2 and
Myl3), known to play a cytoskeletal stabilizing role, were significantly upregulated in both sexes
(RNA-Seq) following IA rhPRG4. Chondrocyte mitochondrial dyscrasias attributable to the arthrosis
in CACP may be mitigated by IA rhPRG4. In a supporting in vitro crystal microbalance experiment,
molecular fouling by albumin did not block the surface activity of rhPRG4.
Keywords: PRG4; lubricin; CACP; arthrosis; arthritis; rhPRG4; Prg4−/− ; collagen hybridizing
peptide
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1. Introduction
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Superficial zone chondrocytes and synoviocytes express lubricin (proteoglycan 4—
PRG4), a highly surface-active mucinous glycoprotein responsible for lubricating articular
cartilage. In addition to reducing friction, PRG4 functions to reduce cell adhesion, inhibit
synovial cell overgrowth and hyperplasia, and prevent cartilage–cartilage integration [1,2].
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Camptodactyly-arthropathy-coxa vara-pericarditis (CACP) syndrome is caused by a deficiency in PRG4 inherited as a recessive trait from both parents [3]. These patients have
variable joint involvement, and report joint pain early in the first decade, which increases
after 10 years of age [4]. Mice lacking the orthologous gene Prg4 may serve as an arthrosis
model [5] to understand the joint failure attributable to lack of PRG4 in humans, since
many clinical features are recapitulated [6].
In Prg4−/− [6] and Prg4GT/GT [3] mice, Prg4 deficiency results in increased joint friction [7], synovial hyperplasia [6], and superficial and intermediate zone apoptosis [8,9]. In
humans, CACP leads to precocious cartilage failure [10,11]. CACP may also be considered
an arthropathy that is partially inflammation mediated, as elucidated in animal models
of Prg4 deficiency and as patients with CACP have used non-steroidal anti-inflammatory
medications for pain relief [12–14]. Mutant Prg4 mouse models show cartilage surface
damage as early as 2 weeks of age [7] and increased whole joint friction by 2 months,
indicating alteration in the whole joint mechanics early in life [15]. Prg4-deficient joints may
experience elevated friction from articular biofouling with albumin and other synovial fluid
non-lubricating proteins [6]. Reactive oxygen species are generated from chondrocytes
subjected to friction-induced mechanical shear [8,16].
Studies in the Yucatan minipig have demonstrated the efficacy of intra-articular (IA)
injection of recombinant human lubricin (rhPRG4) to reduce collagen type II degradation,
cartilage damage, and interleukin 1 beta (IL-1β) levels locally and systemically following a medial meniscus injury [5]. A within-group analysis of Prg4−/− mice receiving
rhPRG4 via IA injection found lower whole joint friction in the injected knee compared
to the contralateral joint [8]. PRG4-deficient synovial fluid from patients with chronic
osteoarthritis (OA) had significantly diminished cartilage boundary-lubricating ability,
which was restored when supplemented with PRG4 purified from bovine explants, in a
cartilage-on-cartilage friction test [17]. The IA injection of human synoviocyte PRG4 in
ACL-transected rat joints restored symmetrical gait compared to transected rats that only
received phosphate-buffered saline (PBS) IA injection [18]. A characteristic limitation of
these studies is that typically, only one joint is affected or injected.
Changes in gait have previously been reported in a case report of CACP involving
facet joint arthropathy and bony ankylosis [19]. The characterization of gait modifications
has been explored in OA, where pain and compensation in gait protect injured limbs from
loading, preventing loss of articular cartilage and formation of osteophytes by altering
internal joint mechanics [20]. Given the important role of PRG4 in boundary lubrication and
joint biomechanics, we sought to characterize the gait disturbances attributable to a lack of
Prg4 in an orthologous mouse model. This study hypothesized that Prg4−/− mice would
demonstrate a reversible quadruped gait change accompanied by reversal of mitochondrial
stress in apoptotic chondrocytes, as assessed by RNA-Seq and immunohistochemistry
following rhPRG4 injection of both hindlimbs. This study served as an initial effort to
determine if IA rhPRG4 holds any therapeutic promise in treating CACP in an appropriate
animal model that shares several clinical features of CACP syndrome [6].
2. Results
2.1. Gait and Posture Indices of Prg4−/− and Prg4+/+ Mice
Significant differences in gait were found between Prg4−/− and Prg4+/+ male mice
in five gait parameters (Table 1). Male Prg4−/− mice had a decreased percent of stride in
braking (p < 0.001), increased percent of stride in propulsion (p < 0.001), increased swing
time (p = 0.048), decreased brake time (p < 0.001), and increased propel time (p < 0.001),
compared to male Prg4+/+ mice. In female Prg4−/− and Prg4+/+ mice, significant differences were found in five parameters (Table 1). Female Prg4−/− mice also showed an increased
percent of stride in propulsion (p = 0.007), increased swing time (p < 0.001), and decreased brake
time (p < 0.001), compared to female Prg4+/+ mice. Female Prg4−/− mice showed a decrease in
stance time (p < 0.001) and stride time (p < 0.001) compared to Prg4+/+ female littermates, which
is different from the male Prg4−/− mice, which showed increases in these parameters.
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Table 1. Difference in hindlimb gait between Prg4−/− and Prg4+/+ mice by sex.
Male
Mean (SD)

Female
Mean (SD)

PSwingStride (%)
Percent of the stride in the swing phase
Prg4−/−
Prg4+/+
p-value (Group differences within Sex)
p-value (Group by Sex Interaction)

37.1
36.1

PBrakeStride (%)
Percent of the stride in the brake phase
Prg4−/−
Prg4+/+
p-value (Group differences within Sex)
p-value (Group by Sex Interaction)

12.5
19.5

PPropelStride (%)
Percent of the stride in the propel phase
Prg4−/−
Prg4+/+
p-value (Group differences within Sex)
p-value (Group by Sex Interaction)

50.4
44.4

Stance/Swing
Stance time divided by swing time
Prg4−/−
Prg4+/+
p-value (Group differences within Sex)
p-value (Group by Sex Interaction)

1.71
1.78

Swing Time (s)
The time for forward portion of the stride in which the paw is not in contact with the belt
Prg4−/−
Prg4+/+
p-value (Group differences within Sex)
p-value (Group by Sex Interaction)

0.077
0.072

(0.015)
0.089
(0.004)
(0.006)
0.072
(0.006)
0.048
<0.001
<0.001

Stance Time (s)
The time for portion of stride where the paw remains in contact with the belt
Prg4−/−
Prg4+/+
p-value (Group differences within Sex)
p-value (Group by Sex Interaction)

0.131
0.127

(0.008)
0.118
(0.008)
(0.007)
0.134
(0.005)
0.185
<0.001
<0.001

Stride Time (s)
The amount of time needed to complete one full stride for one limb
Prg4−/−
Prg4+/+
p-value (Group differences within Sex)
p-value (Group by Sex Interaction)

0.208
0.198

(0.016)
0.190
(0.011)
(0.012)
0.223
(0.006)
0.058
<0.001
<0.001

(2.1)
(1.3)

38.0
39.7

0.198

(1.3)
(1.4)
0.098

0.038

(2.5)
(3.9)

13.4
15.4

<0.001

(1.8)
(1.6)
0.107

0.003

(2.5)
(4.1)

48.6
44.9

<0.001

(2.3)
(1.1)
0.007

0.184

(0.15)
(0.10)

1.65
1.51

0.247

(0.16)
(0.08)
0.059

0.029

Brake Time (s)
The time between initial paw contact with the belt and the maximal paw contact
Prg4−/−
Prg4+/+
p-value (Group differences within Sex)
p-value (Group by Sex Interaction)

0.026
(0.004)
0.025
(0.003)
0.039
(0.008)
0.034
(0.004)
<0.001
<0.001
0.186

Propel Time (s)
Time between maximal paw contact and the end of the stance, just before swing
Prg4−/−
Prg4+/+
p-value (Group differences within Sex)
p-value (Group by Sex Interaction)

0.105
(0.010)
0.093
(0.009)
0.088
(0.009)
0.100
(0.003)
<0.001
0.106
<0.001

Male (Prg4−/− N = 24, Prg4+/+ N = 9); Female (Prg4−/− N = 20, Prg4+/+ N = 5). p-values correspond to test for
group difference in change from baseline. rhPRG4 Injected N = 22; PBS Injected N = 21.
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Other gait parameters that did not show significant changes in comparing Prg4−/−
and Prg4+/+ mice in either sex were percent of stride in swing, and stance divided by swing.
However, there were significant groupwise comparisons in these parameters across sexes
(Table 1) since percent of stride in swing was larger for Prg4−/− male mice and smaller for
Prg4−/− female mice. Similarly, stance divided by swing was larger for Prg4−/− female
mice and smaller for Prg4−/− male mice.
Changes in Gait and Posture Indices following rhPRG4 Injection in Prg4−/− Mice
In the analysis of the Prg4−/− mice gait data, rhPRG4 injection (N = 12) led to increased
time in the stance phase from baseline to day 3 post-injection compared to mice (N = 12) that
received the PBS injection (p = 0.005). rhPRG4 injection also led to an increased propel time
at day 3 compared to baseline, versus PBS injection (p = 0.020) (Table 2a). Differences between
day 6 post-injection and baseline gait showed no statistical difference between rhPRG4- and
PBS-injected animals. Overall, these results indicate that the male mice were able to spend
more time in stance and in propulsion during their gait. Changes in gait parameters following
IA rhPRG4 were not observed in female mice by day 3 or 6 following injection (Table 2b).
Table 2. (a). Male hindlimb gait data from baseline to 6 days post-injection. (b). Female hindlimb gait
data from baseline to 6 days post-injection.
(a)
Males
Baseline
Mean (SD)

Day 3
Mean (SD)

Day 6
Mean (SD)

PSwingStride (%)
rhPRG4 Injected
PBS Injected
p-value

37.8
36.4

2.2
1.8

36.6
36.5
0.134

2.6
1.2

36.6
36.8
0.077

2.2
1.8

PBrakeStride (%)
rhPRG4 Injected
PBS Injected
p-value

12.4
12.6

2.1
2.9

12.2
13.1
0.544

1.7
2.4

12.3
12.0
0.726

2.8
2.2

PPropelStride (%)
rhPRG4 Injected
PBS Injected
p-value

49.8
51.0

2.2
2.7

51.3
50.4
0.152

3.2
1.5

51.1
51.2
0.441

2.4
2.9

Stance/Swing
rhPRG4 Injected
PBS Injected
p-value

1.66
1.76

0.15
0.14

1.76
1.75
0.099

0.23
0.10

1.74
1.73
0.099

0.16
0.13

Swing Time (s)
rhPRG4 Injected
PBS Injected
p-value

0.079
0.076

0.009
0.010

0.078
0.073
0.742

0.009
0.005

0.074
0.074
0.204

0.007
0.010

Stance Time (s)
rhPRG4 Injected
PBS Injected
p-value

0.130
0.131

0.006
0.010

0.134
0.127
0.005

0.007
0.006

0.127
0.127
0.756

0.004
0.007

Stride Time (s)
rhPRG4 Injected
PBS Injected
p-value

0.210
0.206

0.013
0.019

0.212
0.200
0.080

0.013
0.010

0.200
0.200
0.517

0.010
0.017

Brake Time (s)
rhPRG4 Injected
PBS Injected
p-value

0.026
0.026

0.004
0.005

0.026
0.026
0.835

0.004
0.004

0.025
0.024
0.876

0.005
0.005

Propel Time (s)
rhPRG4 Injected
PBS Injected
p-value

0.104
0.105

0.008
0.012

0.109
0.101
0.020

0.008
0.006

0.102
0.103
0.848

0.006
0.007
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Table 2. Cont.
(b)
Females
Baseline
Mean (SD)

Day 3
Mean (SD)

Day 6
Mean (SD)

PSwingStride (%)
rhPRG4 Injected
PBS Injected
p-value

38.3
37.8

2.6
2.1

37.5
38.5
0.154

1.3
1.3

37.9
38.2
0.401

2.0
2.4

PBrakeStride (%)
rhPRG4 Injected
PBS Injected
p-value

13.0
13.5

1.8
1.8

13.8
12.5
0.240

3.1
3.1

14.6
13.1
0.203

2.4
1.9

PPropelStride (%)
rhPRG4 Injected
PBS Injected
p-value

48.7
48.7

2.5
2.2

48.7
49.0
0.860

2.4
3.1

47.5
48.6
0.412

2.2
2.6

Stance/Swing
rhPRG4 Injected
PBS Injected
p-value

1.63
1.66

0.18
0.15

1.67
1.60
0.202

0.09
0.09

1.65
1.64
0.591

0.15
0.17

Swing Time (s)
rhPRG4 Injected
PBS Injected
p-value

0.072
0.073

0.006
0.006

0.072
0.076
0.388

0.004
0.007

0.071
0.074
0.476

0.009
0.008

Stance Time (s)
rhPRG4 Injected
PBS Injected
p-value

0.116
0.120

0.008
0.009

0.120
0.121
0.522

0.004
0.007

0.116
0.119
0.884

0.011
0.009

Stride Time (s)
rhPRG4 Injected
PBS Injected
p-value

0.189
0.193

0.010
0.012

0.192
0.196
0.968

0.007
0.013

0.187
0.193
0.770

0.019
0.013

Brake Time (s)
rhPRG4 Injected
PBS Injected
p-value

0.025
0.026

0.003
0.002

0.026
0.024
0.189

0.005
0.005

0.027
0.025
0.207

0.004
0.003

Propel Time (s)
rhPRG4 Injected
PBS Injected
p-value

0.092
0.094

0.008
0.009

0.093
0.096
0.904

0.007
0.010

0.089
0.094
0.544

0.010
0.009

p-values correspond to test for male and female group difference in change from baseline. rhPRG4 injected N = 12
male and N = 10 female; PBS injected N = 12 male and N = 9 female.

2.2. Caspase-3 Activation in Superficial Zone Chondrocytes
Immunostaining of joints from male and female Prg4−/− mice for active caspase-3
showed significantly lower immunopositivity in superficial zone chondrocytes from the
knee joint coronal sections of mice that received rhPRG4 IA injection (N = 4 males and
N = 4 females) compared to PBS injection (N = 3 males and N = 7 females) at 10 days
(p < 0.01). For comparison, activated caspase-3 was readily detected in non-injected control
Prg4−/− mice in both sexes. In contrast, Prg4+/+ mice of both sexes show little or no signal
(Figure 1).
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Figure 1. Suppression of caspase-3 activation by rhPRG4 in Prg4−/− mouse joints. (A) Immunostaining for active caspase-3 in representative knee joint coronal sections of 8-week-old Prg4−/−
mice that received IA rhPRG4 or PBS 10 days prior. Note the immunopositivity in superficial zone
chondrocytes (arrow heads) that received PBS contrasted with littermates that received rhPRG4 and
showed a smaller signal. The application of rhPRG4 in Prg4−/− joints serves to reduce mechanical shear stress in both diseased and healthy cartilage. F = femoral condyle and m = meniscus.
(B) Counts of chondrocytes with caspase-3 activation per 100 chondrocytes from both the femoral
and tibial cartilage computed across 10 mice (3♂ and 7♀) treated with PBS and 8 mice (4♂ and
4♀) treated with rhPRG4 10 days after IA injection. (C) Immunostaining for active caspase-3 in
chondrocytes (arrow heads) in representative knee joint coronal sections of 8-week-old non-injected
control Prg4−/− and Prg4+/+ mice. (D) Corresponding counts of chondrocytes with caspase-3 activation in 8-week-old non-injected control Prg4−/− (4♂ and 4♀) and Prg4+/+ mice (4♂ and 4♀).
Mean ± SD displayed. ** p < 0.01.

2.3. RNA-Seq Analysis of Recovered Articular Cartilage in Male and Female Prg4−/− Mice
following rhPRG4 Injection
The statistics of the mapping of reads to the reference genome are illustrated in
Supplementary Table S1. In comparing male rhPRG4- and PBS-injected mice, 22 significantly differentially expressed genes were identified, as illustrated in Figure 2 and identified
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in Supplementary Table S2. Genes that were upregulated in male rhPRG4-injected mice
compared to PBS mice were Prg2, Fam129c, Myh7, Igkc, Gbp4, and Xist. Downregulated
genes were Scube1, Wif1, Matn3, Cxcl14, Hapln1, Mss51, Col2a1, Tnn, Sfrp2, Col12a1, Mmp13,
Kdm5d, Uty, Ddx3y, Eif2s3y, and Amd1. Selected confirmatory qRT-PCR for Myh7 and
Xist showed a relative fold expression change of 24.8 and 51.8, respectively, compared to
cartilage from control tibio-femoral joints that received IA PBS.

Figure 2. RNA-Seq analysis of chondrocytes recovered from individual male and female Prg4−/−
mice treated with either rhPRG4 or PBS. (A) Bi-clustering heat map of differentially expressed genes
assorted by their adjusted p-values for both sexes and (B) Log2 fold change in genes in PBS vs.
rhPRG4 from RNA-seq data for both sexes. Heatmap colors represent the log2 expression values of
each group for each gene. Groups were clustered based upon their similar expression values and
presented as dendrograms. In total, 34 and 22 known significantly differentially expressed genes
were identified in female and male Prg4−/− mice, respectively.

In comparing female rhPRG4- and PBS-injected mice, there were 34 significantly differentially expressed genes, as illustrated in Figure 2 and identified in Supplementary Table S2.
Upregulated genes in female rhPRG4-injected mice compared to PBS mice were Myl2,
Matn3, Rgs9, Tnni1, Hmgn5, Alox12b, Lars2, Ccdc33, Pkhd1, Pou4f1, Igfn1, Cytl1, Mt-tv, Mt-tl2,
and Mt-tp. Downregulated genes were Mapt7d2, Snora73a, Snora23, Snord118, Snora21, Rny3,
Snord104, Vaultrc5, Rnu12, Rny1, Snord15a, Snora57, Snora17, Snord17, Snord13, Snora78,
Scarna6, Scarna3a, and Asmt. Selected confirmatory qRT-PCR for Lars2, Myl2, and Tnni1
showed a relative fold expression change of 5.4, 3350.2, and 950.6, respectively, compared
to cartilage from control tibio-femoral joints that received IA PBS.
In pooled-sex rhPRG4- and PBS-injected mice, there were several significantly differentially expressed upregulated genes, as illustrated by the Volcano plot (Figure 3A) and
identified in Supplementary Table S2. These included Myh7, Mt-tn, Igfn1, Myl2, Myl3,
Tnnc1, Tnni1, and Tnnt1.
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Figure 3. Analysis of merged RNA-Seq data (both sexes PBS vs. rhPRG4) of chondrocytes from
male and female Prg4−/− mice of differentially expressed genes, assorted by their adjusted p (padj)
values independent of sex, treated with rhPRG4 compared to PBS. (A) Volcano plot of differentially
expressed genes, where padj < 0.05 genes are labeled in red. (B) GeneMANIA Cytoscape interaction
network of genes associated with the significantly upregulated core node genes (cross-hatched circles).
Line color depicts gene co-expression (purple), predicted association (orange), and co-localization
(blue). Supplementary Tables S2 and S3 illustrate the associated gene identities, which include
cytoskeletal and mitochondrial genes, associated with mitochondrial metabolism or associated with
mitochondrial DNA. Troponin I1 (Tnni1) has been previously associated with CACP syndrome in
humans. Note that mt-Tn and Gm25747 (predicted gene) were not selectable in the GeneMANIA
database and thus not incorporated as core node genes.

2.4. qRT-PCR of Nerve Growth Factor and Apoptotic Genes from Recovered Synovium
The synovium of Prg4−/− mice injected IA with rhPRG4 as opposed to PBS had
decreased expression of nerve growth factor (Ngf ) at day 10 (p = 0.006) but not day 20
(p = 0.104) (Figure 4). The expression of B cell lymphoma 2 (Bcl2) was increased by rhPRG4
injection by day 20 post-injection (p = 0.001), with differences at day 10 post-injection that
trended towards significance (p = 0.065). Interestingly, the expression of heat shock proteins 27,
70, and 80 (Hsp27, Hsp70, Hsp90) were significantly decreased at both day 10 (Hsp27 p = 0.042,
Hsp70 p = 0.017, Hsp90 p = 0.008) and day 20 (Hsp27 p = 0.019, Hsp70 p = 0.025, Hsp90 p = 0.009)
in synovium from rhPRG4-injected animals compared to PBS-injected animals. Poly(ADP)ribose polymerase-1 (Parp) and caspase-activated DNase (Cad) were both significantly decreased in the synovium of rhPRG4- vs. PBS-injected animals at days 10 (p = 0.028) and 20
(p = 0.011) for PARP and at day 10 for CAD (p = 0.007). BH3 interacting-domain death agonist
(Bid) decreased at day 20 and approached significance (p = 0.056).
2.5. Accumulation of Collagen-Binding Protein in the Superficial Zone
Probing the IA-injected Prg4−/− tibio-femoral joints with a collagen-binding peptide [21] sourced from 3Helix (Salt Lake, UT, USA) revealed more binding and thus degradation of collagen throughout the joint. This was especially pronounced qualitatively in
the superficial zone (Supplementary Figure S1). Segmenting the fluorescence signal and
optimizing the quantitation [22] in the superficial zone to a depth of 10 µm from the surface, and across the femoral and tibial condylar surfaces revealed that the rhPRG4-treated
Prg4−/− joints from combined male and female mice showed significantly less degradation
or overturn of collagen.
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Figure 4. Quantitative real-time PCR of apoptosis mediators in synoviocytes from rhPRG4-injected
Prg4−/− mouse knees. The ∆∆Ct calculation represented as a log2 fold change relative to Prg4−/−
littermates injected with PBS. Synovium samples were pooled from rhPRG4-injected N = 3 and
PBS-injected N = 3 mice at 10 and 20 days following IA injection. Mean ± SEM displayed. * p < 0.05.

2.6. Quartz Microbalance Measurements for Adsorption and Anti-Adhesion
The mean ∆F of bovine serum albumin (BSA) (−0.53 ± 16.0 Hz) was significantly
lower than ∆F for rhPRG4 (−49.0 ± 23.0 Hz) and rhPRG4DTT (−46.0 ± 18.0 Hz) (p < 0.05),
showing that both preparations of rhPRG4 were more surface active than BSA (Figure 5).
No significant differences were observed between rhPRG4 alone and rhPRG4 followed by
BSA or for rhPRG4DTT followed by BSA. The mean ∆F of BSA followed by rhPRG4DTT
(−75.0 ± 38.0 Hz) (p < 0.05) was significantly different from BSA. The ∆F of BSA followed
by rhPRG4 (−19.0 ± 16.0 Hz) was not as large and significantly different (p < 0.05) (Figure 5).
The dithiothreitol (DTT) treatment of rhPRG4 served to monomerize PRG4.

Figure 5. Anti-adhesive activity of rhPRG4 and DTT-treated rhPRG4 (rhPRG4DTT ) in the quartz
crystal microbalance. Mean ∆F values, a measure of the amount of adsorption on the crystal surface, of
BSA, rhPRG4, and rhPRG4DTT are shown along with ∆F measurements on surfaces coated with either
rhPRG4 or rhPRG4DTT followed by BSA or vice versa. Mean ∆F was unaffected by BSA compared to
rhPRG4 (p < 0.05) and rhPRG4DTT (p < 0.05). Mean ∆F of rhPRG4 was not significantly different from
rhPRG4DTT (p > 0.05). Mean ∆F of BSA on an rhPRG4 coated surface was not significantly different from
rhPRG4 adsorption alone (p > 0.05). Mean ∆F of rhPRG4DTT on a BSA-coated surface (BSA + rhPRG4DTT )
was significantly lower compared to BSA (p < 0.05). Mean ± SD displayed. * p < 0.05.
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3. Discussion
CACP is a syndrome of precocious arthropathy that is initiated by a lack of the lubricating glycoprotein PRG4, secreted by synovial fibroblasts and superficial zone chondrocytes.
PRG4 provides boundary lubrication on the articular cartilage surface [23,24]. The synovial
fluid in patients with CACP syndrome is rich in hyaluronic acid [7], which by itself, similar
to other synovial fluid constituents, is unable to provide full chondroprotection. Patients
with CACP either do not express PRG4 or express a variant that does not function due to
mutations in the mucin or hemopexin domain [2,25]. This preclinical study of rhPRG4 in
Prg4−/− mice offers our first insights into whether rhPRG4 shows activity in this inherited
arthrosis in an orthologous animal model.
Describing the gait characteristics of Prg4−/− mice is an important step to evaluate
the functional implications of CACP and future therapeutic attempts. This investigation
revealed that the phenotypic arthrosis resulting from the Prg4−/− state from birth differs
between male and female mice (Table 1). Some gait parameters only showed phenotypic
differences in one sex but not the other, such as the decrease in stance time for Prg4−/−
females compared to Prg4+/+ female littermates, whereas other gait parameters were more
similar between the sexes. The IA rhPRG4 increased the stance and propulsion time in
Prg4−/− male mice by day 3 following hindlimb knee injection (Table 2a). Female mice
did not respond in a similar manner to the IA rhPRG4 (Table 2b). Six days after the IA
rhPRG4, neither male nor female Prg4−/− mice showed any effects on quadruped gait.
These observations coincided with the reversal of caspase-3 activation in superficial zone
chondrocytes in both sexes 10 days following IA injection (Figure 1). This observation
also recapitulates a previous study of mitochondrial dysregulation in Prg4−/− gene trap
mice that also observed activation of caspase-3 in chondrocytes that was reversible upon
conditional Prg4 expression [8].
PRG4 works by lubricating articular surfaces, alleviating the mechanical shear of
underlying superficial zone chondrocytes and thus lessening mitochondrial stresses, and
ultimately caspase-3 activation. Caspase inhibitors have already been identified as having
disease-modifying roles in human OA [26]. The present results are partly biophysical in
nature through the alleviation of friction-induced exaggerated mechanical deformation
upon mitochondria within superficial zone chondrocytes, which our laboratory [8,9] and
others [27] have described. Deformation is exaggerated in high-friction states caused by
stick-slip phenomenon at near zero low sliding speeds, forming adhesion bridges in the
absence of Prg4, which may damage collagen at the surface of cartilage. The observed
affinity of collagen hybridizing peptide to the superficial zone (Supplementary Figure S1)
appears to support a mechanical damage mechanism [21], although remodeling [28] is also
possible. Thus, the quartz microbalance was used to measure the surface activity of rhPRG4
as a change in the resonant frequency of a quartz crystal substrate. Albumin showed
no effect, which is known to biofoul articular cartilage [6] in the Prg4−/− joint in lieu of
chondroprotective Prg4 (Figure 5). The rhPRG4 has a higher binding affinity than BSA [29]
due to its surface-active nature, and likely explains why cartilage from Prg4−/− mouse
joints are characteristically fouled with a layer(s) of albumin and gamma globulin [3,6].
The observed in vitro biophysical activity at the hydrophilic–hydrophobic interface may
recapitulate the SF–cartilage interface since the latter has a hydrophobic character [30]. The
quartz microbalance experiments show that rhPRG4 binds avidly to an interface and does
so despite pre-existing biofouling albumin, possibly recapitulating a similar effect on CACP
cartilage surfaces. Monomerizing the rhPRG4 through disulfide bond reduction via DTT
showed an even larger effect.
The pooled-sex articular cartilage RNA-Seq data indicates that the expression of Mt-tn
was increased following IA rhPRG4 and is a component of the mitochondrial enzyme
Complex 1 necessary for protein synthesis [31]. Surprisingly, myosin-related proteins,
such as Myh7, and troponin subunits Tnnc1 and Tnnt1 were significantly upregulated
(Figures 2 and 3) following IA rhPRG4. This is important since non-muscle myosin heavy
chains contribute to mitochondrial DNA maintenance [32]. Both Tnnc1 and Tnnt1 are
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also involved in organizing cytoskeletal actin, playing roles in cellular traction and migration [33]. Together, these cellular subunits, better known for their function in the sarcomere,
may play a fundamental role in stabilizing the mitochondria. In addition, Troponin I1
(Tnni1) slow skeletal type has a known association with CACP in humans [34]. The GeneMANIA [35] co-expression and association analysis (Figures 3B and S2) supports this
conclusion since other subcellular and cytoskeletal genes are associated with mitochondria
DNA, such as xin actin-binding repeat containing 1 (Xirp1) [36], mitochondrial biogenesislike sarcolipin (Sln) [37], and ankyrin repeat domain 2 (Ankrd2) [38]. Other associated
genes from the GeneMANIA analysis are caspase-3, which is central to our overarching
hypothesis; mitochondrial creatinine kinase (Ckmt2) [39]; leucine-rich repeat; sterile alpha
motif-containing 1 (Lrsam 1) [40]; and pleckstrin homology domain-containing family F
(Plekhf1) [41], which are respectively involved in mitochondrial metabolism and cell death
via the Plekhf1-dependent lysosomal-mitochondria pathway. The gene Lars2, enhanced
by rhPRG4 in the female RNA-Seq data, is responsible for mitochondrial leucyl tRNA
synthetase 2 expression [42].
The behavioral results of the present study parallel an earlier study of IA injection of
hyaluronan for symptomatic relief in a murine model of OA [43] conducted in C57BL/6
male mice, aged 12 weeks, that also showed an acute and prolonged increase in swing and
stance times by hyaluronan after the induction of OA. However, that study used a walking
speed of 18 cm/s at a 17 degree uphill gradient, as opposed to the present study’s 28 cm/s
at no incline. A model of rheumatoid arthritis in DBA/1LacJ mice showed significantly decreased swing, stride, stance, and propulsion time across more severe gradations of arthritis
in female mice [44]. Among other studies that utilized DigiGait in a mutant mouse model,
a shortened stance time was observed in mice lacking CX3CR1 resulting in phenotypic
hip dysplasia [45]. A decrease in stance time was also observed in mice that received IA
carrageenan, thus correlating decreased stance time with mechanical allodynia [46].
One of the main complaints from CACP patients is pain, with increased pain levels after age 10 [4]. Most patients are treated with NSAIDs and others may be treated
with immunosuppressants or anti-inflammatory biologics, such as etanercept [25]. These
treatments show little effect apart from mild pain relief [14]. In the present study, the IA injection of rhPRG4 decreased NGF expression by synoviocytes at day 10. The improved gait
characteristic in male mice resulting from IA rhPRG4 injection may be associated with less
nociceptive pain as reported in rodent studies [47,48]. The disparity in locomotor behavioral
effects between male and female mice in experimental arthritis models has been observed
before [49,50]. Nociceptive pain is sex dependent and related to the cross talk between
afferent neurons in the synovium and infiltrating immune cells, such as macrophages [51].
Female rodents generate a greater immune response than male counterparts, involving both
innate [52] and adaptive immunity [53]. Thus, females may experience more mechanical
allodynia, generate less joint loading, and thus less cartilage degeneration occurs. This may
also explain why at baseline, female Prg4−/− mice (Table 1) demonstrated a shorter stance
time than female Prg4+/+ and male Prg4−/− littermates. In male rodents, innate immunity
is TLR receptor dependent, where TLR antagonists suppressed mechanical allodynia in
only male mice in nerve injury studies [53]. In the arthritic joint, aggrecan fragments are
thought to produce pain through a TLR2 interaction [54]. This is particularly relevant for
the present study since PRG4 is a TLR2 and TLR4 antagonist [55,56], and regulates synovial
macrophage polarization by diminishing the numbers of synovial M1 macrophages [57].
The RNA recovered from the present lubricin-null joints shows that synovium from
Prg4−/− mice treated with rhPRG4 show more Bcl2 and less Cad (Figure 4), indicating
stabilization of the mitochondria. The trending decrease of Bid by day 20 post-injection also
suggests an anti-apoptotic action for the cell cycle, indicating that anastasis, the reversal of
apoptosis, may have occurred. Traditionally, programmed cell death caused by apoptosis
has been considered an irreversible process, involving the release of mitochondrial cytochrome c
into the cytosol and the activation of execution caspases, such as caspase-3. However, emerging
evidence suggests that cells undergoing programmed cell death can recover [58].
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Despite the regulation of some pro-apoptotic and anti-apoptotic factors to reverse
apoptosis, other anti-apoptotic factors, such as Parp and the heat shock proteins Hsp27,
Hsp70 [59], and Hsp90, were downregulated in the synovium. Upstream, at the level of
the apoptosis inducers, reactive oxygen species (ROS)-, reactive nitrogen species (RNS)-,
and tumor necrosis factor α (TNFα)-induced chondrocyte apoptosis plays a major role [60].
Evidence for TNFα-induced chondrocyte apoptosis has been found in the pro-apoptotic
action of TNF-related apoptosis-inducing ligand receptors (e.g., DR4 and DR5) both in vitro
and in vivo. This was accompanied by active caspase-3 immunoreactivity, cytochrome c
release, and cleavage of PARP [61,62]. The TNFα-induced chondrocyte apoptosis pathway
is also associated with ROS generation in OA chondrocytes, as the mitochondrial protein
TNFα-receptor-associated protein 1 (TRAP1), a member of the HSP90 family, was found
in high abundance in those chondrocytes. The function of TRAP1 to antagonize ROS in
protection against oxidative stress-induced apoptosis may signify the redox imbalance of
the cellular environment [63]. Part of PRG4’s anti-apoptotic effects can also be attributed to
inhibition of the TNFα-induced chondrocyte apoptosis pathway, as PRG4 is known to bind
to CD44 to prevent the expression of TNFα [64].
ROS and RNS lead to mitochondrial dysfunction and are generated by stressed mitochondria. Peroxynitrite is a reaction product of nitric oxide and superoxide anions leading
to induction of chondrocyte apoptosis [65,66]. Furthermore, ROS itself activates caspase-3like proteases and caspase-3 [67]. When Prg4 gene trap mice, postnatally in a Prg4−/− state,
were recombined to re-express Prg4 later in life, cartilage in their tibiofemoral joints had
a significantly reduced peroxynitrite content and caspase-3-positive staining, compared
to Prg4−/− littermates [68]. ROS are associated with mitochondrial dysfunction as the
electron transport chain slows with decreased activity at Complex I, II, and III, which may
be implicated in excess chondrocyte generation of ROS and RNS [69,70]. As such, the chondroprotective effects of PRG4 may also be due to decreased mitochondrial DNA damage
and increased repair [69]. PRG4, autophagy, and antioxidant defense could be linked, as
one study found that FoxO transcription factors modulate these factors simultaneously and
synergistically with transforming growth factor-β stimulation [71].
Limitations of this study revolve around studying a temporizing treatment in an
animal model that already shows advanced disease. In addition, the vagaries of gender
in arthritis animal models may have also occurred in this study. Potentially limiting the
strength of the effect of IA rhPRG4 is the analysis of quadruped gait following bilateral
hindlimb injections. However, the maturation of gait in mice studied in the DigiGait
parallels normal human gait development in terms of the percent of stride in the stance
and swing phase [72] and yet other DigiGait studies of monoarthritis have failed to show
measurable changes in gait [73] but used a slower treadmill speed than the present study.
We also do not know how much of the rhPRG4 was retained on the articular surfaces given
the prolonged tissue phase half-life of rhPRG4 [74]. An immunohistochemical approach is
not readily available since many of the immunoprobes were developed in mice [75] and
cross reacted with the biofouling protein (data not shown).
In conclusion, the IA injection of rhPRG4 may offer some benefit to young patients with
CACP judging by the correlation between inhibition of caspase-3 activation in chondrocytes
and the observed quadruped gait improvement in stance and propulsion in male mice.
The re-introduction of the missing functional protein in the orthologous murine disease
model provides proof of principle of a therapeutic potential that is partially dependent on
reversing mitochondrial dysfunction [76]. Patients with CACP typically seek rheumatologic
evaluation given their multiple joint complaints. Currently, no treatments exist to restore
this essential mucinous glycoprotein, although both helper-dependent virus [77] and adenoassociated virus [78] approaches exist and rhPRG4 has been used in a prior clinical trial [79].
There remains a need for more clinical information on the progression of CACP syndrome
with advancing age both in childhood and beyond. In addition, information is lacking
regarding the long-term consequences of heterozygosity for PRG4 mutations in the family
members of affected individuals.
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4. Materials and Methods
4.1. Prg4−/− Mice
Mice with a mutant Prg4 allele were created by homologous recombination in 129Sv/Evderived embryonic stem cells as described previously [6], resulting in the replacement
of Prg4 exon 6 with lacZ and neo. The genetic identity of progeny from the mating of
Prg4+/− and Prg4+/− littermates was analyzed by a PCR-based genotype assay used previously [6]. Mice were euthanized following CO2 inhalation and their joints were removed
and processed immediately after. All procedures for mouse research were approved by
the Institutional Animal Care and Use Committee of Rhode Island Hospital. Here, 7- to
8-week-old Prg4−/− mice (24 male and 20 female) and 7–8-week-old Prg4+/+ mice (9 male
and 5 female) were used in gait, knee joint injection, and tissue studies. A random selection
of these animals were euthanized 10 and 20 days following joint injection for histological
studies and synoviocyte RNA collection. An additional 6 male and 6 female 7–8-week-old
Prg4−/− mice were used in the RNA-Seq gene expression studies.
4.2. Manufacture and Purification of rhPRG4
The expression of rhPRG4 by CHO-M cells has been described previously [80]. CHO-M
cells were transfected with plasmid vectors (Selexis SA, Geneva, Switzerland) containing the
human PRG4 gene, 1404 amino acids in length, under the control of hEF-1-alpha promoter
coupled to a CMV enhancer [81]. The presence of O-linked glycosylations comprising
(β1,3) Gal-GalNAc was previously confirmed by mass spectrometry [81]. rhPRG4 that
was disulphide bond reduced (rhPRG4DTT ) was prepared by incubating 2 mg/mL rhPRG4
with 10 mg/mL dithiothreitol for 2 h at 60 ◦ C. rhPRG4 used in animal studies was filtered
through a 0.22 µm filter prior to use.
4.3. In Vivo Tribosupplementation of Prg4−/− Mouse Knees
For the 24 male and 20 female Prg4−/− mice injected with either rhPRG4 or sterile
PBS, the mice were anesthetized under isoflurane (3–5%), and a 70% alcohol wash used
to prepare the site of injection. The knee was held in flexion and 10 µL of either rhPRG4
(2.0 mg/mL) or sterile PBS were injected via a 31G needle through the patellar tendon,
confirmed by distension of the joint space. The needle was removed, and the knee was
flexed and extended 10 times, distributing the injected fluid evenly throughout the joint
cavity. Both hindlimbs were injected.
4.4. Gait Analysis
In this study, 7- to 8-week-old Prg4−/− mice (24 male and 20 female) and 7–8-week-old
mice (9 male and 5 female) were studied in the DigiGait gait analysis system
(Mouse Specifics Inc, Framingham, MA, USA). The instrument allows mice to walk on
a transparent treadmill belt. Underneath the belt a video camera captures the ventral
side of the animal as it walks. DigiGait automatically detects and vectorizes the animal’s
paws based on their pink coloration. The software uses image recognition and artificial
intelligence algorithms to create a set of periodic waveforms describing the placement of
the four limbs through consecutive strides. The software then analyzes the gait dynamics
for 31 different postural and kinematic metrics of gait as described previously [82].
For each measurement collection, mice were ambulated at 28 cm/s with 0 degrees tilt
for 30 s. Gait parameters included swing time (non-weight bearing phase of gait), percent
of stride in swing, brake time, percent of stride in breaking, propulsion time, percent of
stride in propulsion, stance time (weight bearing phase of gait), stance time/swing time,
and stride time. The Prg4−/− and Prg4+/+ mice were measured at baseline. The following
day, half of the Prg4−/− mice were randomly selected and injected IA in both hindlimbs
with rhPRG4, and the other half of the Prg4−/− mice were injected IA with PBS. Gait
measurements were performed on days 3 and 6 post-injection by an operator blinded to
the treatment identity.
Prg4+/+
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4.5. Tissue Processing for Immunohistochemistry of Caspase-3 and Collagen Hybridizing Peptide
On day 10 post-injection with either rhPRG4 or PBS, knee joints were dissected out and
fixed in 10% formalin (Fisher PROTOCOLTM , Thermo Fisher Scientific, Waltham, MA, USA)
and decalcified using a solution of 0.48M EDTA, with an adjusted pH of 7.1 with ammonium
hydroxide at 4 ◦ C for 48 h. Coronal sections (5 µm), framing the femoral condyles and
tibial plateau, were taken for histological analysis of caspase-3 activation. Sections were
incubated at 60 ◦ C for 30 min, deparaffinized, and hydrated in 3 cycles of xylene and serial
alcohol. Incubation in a pepsin solution (Thermo Fisher Scientific, Waltham, MA, USA)
allowed for antigen retrieval. A 1:1000 dilution of rabbit polyclonal antibody against active
caspase-3 antibody 961 (Cell Signaling Technology, Danvers, MA, USA) was added for
incubation at 4 ◦ C overnight. After 3 washes with PBS, the sections were incubated for
1 h in 1:1000 dilution of Cy3 goat anti-rabbit IgG at room temperature (Life Technologies,
Molecular Probes, Eugene, OR, USA). After another five washes with PBS, the sections
were counterstained using Vectashield mounting media with DAPI (Vector Laboratories
Inc., Burlingame, CA, USA). Adjacent sections were also probed with collagen hybridizing
peptide (3Helix) [21,83] using the manufacturer’s recommendations, imaged using Image
Pro 9.3 (Media Cybernetics, Rockville, MD, USA), and counted as described previously [84].
4.6. Quantitative Real-Time Polymerase Chain Reaction of Synovial RNA
First, 2 groups of N = 3 mice from the above rhPRG4- and PBS-injected animals were
euthanized separately 10 and 20 days following IA injection. Messenger RNA (mRNA)
was isolated from the knee synovium of both hindlimbs following homogenization in
2 60 s periods at 60 Hz using a KZII homogenizer (Servicebio, Wuhan, China) interspersed
by a 60 s incubation at 4 ◦ C. RNA was extracted and purified using an RNeasy mini kit
(Qiagen, Germantown, MD, USA). Total RNA was obtained for each group of 3 mice and
measured by a Nanodrop 2000c (Thermo Scientific, Waltham, MA, USA). The samples were
pooled by injection group for qRT-PCR analysis using the cDNA primers summarized in
Supplementary Table S3 and manufactured by MilliporeSigma (Burlington, MA, USA). The
cycle threshold (Ct) value of genes of interest was normalized to the Ct value for GAPDH in
the same sample and the relative expression was calculated using the 2−∆∆Ct method [85].
4.7. RNA-Seq Analysis of Chondrocyte RNA
The additional 6 male and 6 female Prg4−/− mice described above were injected with
rhPRG4 or PBS by block randomization, which resulted in 2 rhPRG4 and 2 PBS groups of
3 mice each sharing the same sex. Ten days later, cartilage was obtained and pooled from
three mice sharing the same sex and IA treatment. The cartilage was homogenized in 2 60 s
periods at 60 Hz using a KZII homogenizer (Servicebio, Cambridge, MA, USA) interspersed
by a 60 s incubation at 4 ◦ C. RNA was extracted and purified using an RNeasy mini kit
(Qiagen, Germantown, MD, USA). Total RNA was obtained for each group of 3 mice and
measured by a Nanodrop 2000c (Thermo Scientific, Waltham, MA, USA). In total, 5 µg of
total RNA from each group were used for RNA-Seq analysis performed by GENEWIZ (South
Plainfield, NJ, USA), who were blinded to the group identity. Library preparation completed
at GENEWIZ utilized PolyA selection and rRNA depletion. Furthermore, 150 bp paired-end
sequencing was performed on an Illumina HiSeq (Illumina Inc., San Diego, CA, USA).
Sequence reads were trimmed to remove possible adapter sequences and nucleotides
with poor quality using Trimmomatic v.0.36 (Anthony Bolga and Bjorn Usadel, Aachen,
Germany). The trimmed reads were mapped to the Mus musculus GRCm38 reference
genome available on ENSEMBL using the STAR aligner v.2.5.2b (Alex Doblin, Cold Spring
Harbor Laboratory, Cold Spring Harbor, NY, USA) and BAM files were generated. Unique
gene hit counts were calculated by using feature counts from the Subread package v.1.5.2
(Alex Doblin, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, USA). The hit counts
were summarized and reported using gene_id and only unique reads that fell within exon
regions were counted. Since a strand-specific library preparation was performed, the reads
were strand-specifically counted.
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After the extraction of gene hit counts, a gene hit counts table was used for downstream
differential expression analysis. Using DESeq2, a comparison of the gene expression
between rhPRG4 and PBS in both sexes was performed. Confirmatory qRT-PCR was
performed and relative fold changes for both IA rhPRG4- and PBS-injected limbs were
calculated using the 2−∆∆Ct method [85] on identified upregulated genes of interest from
the analysis of both sexes. Supplementary Table S3 illustrates the cDNA primers used. The
primer pairs for Xist (Cell Signaling Technology) and Lars2 (OriGene, Rockville, MD, USA)
were sourced commercially. The primer sequence for Myh7 was used previously [86].
4.8. Gene Ontology Analysis
A gene ontology analysis was performed on the statistically significant set of genes
by implementing the software GeneSCF v.1.1-p2 (Santhilal Subhash, Cold Spring Harbor
Laboratory, Cold Spring Harbor, NY, USA). The mgi GO list was used to cluster a set of
genes based on their biological processes and determine their statistical significance. A list
of clustered genes was generated based on their gene ontologies.
4.9. Adsorption and Anti-Adhesion by rhPRG4 Using Quartz Crystal Microbalance
The non-specific adsorption and anti-adhesive properties of rhPRG4 were measured using
QCM 200 (Stanford Research Systems, Sunnyvale, CA, USA) as described by Greene et al. [87].
This method consisted of the following steps: a quartz crystal microbalance Cr/Au 5 MHz
(part#6-613, Stanford Research Systems) wafer was equilibrated with PBS at a constant
flow rate of 300 µL/min; either 1 mL of rhPRG4 (diluted with PBS to a concentration
of 300 µg/mL) or bovine serum albumin (BSA) (300 µg/mL) was infused into the QCM
flow cell; a 20 min incubation followed, after which the crystal was equilibrated with
PBS until a stable frequency baseline was achieved; either 1 mL of 300 µg/mL of BSA or
rhPRG4 was introduced followed by another 20 min incubation and PBS equilibration. The
difference in frequency, ∆F (measure of adsorption), of the QCM crystal was measured
using a customized MATLAB algorithm. ∆F values for BSA on a rhPRG4- or rhPRG4DTT coated surface and vice versa were determined. Moreover, ∆F values for BSA, rhPRG4,
and rhPRG4DTT were obtained using control experiments, wherein the steps were the same
except that the samples were followed by 1 mL of PBS.
4.10. Statistics
Hindlimb gait measurements were compared between Prg4−/− and Prg4+/+ mice
using two-way analyses of variance with type (Prg4−/− vs. Prg4+/+ ) and sex as fixed
factors. Comparisons between Prg4−/− mice injected with rhPRG4 and those injected
with PBS were based on mixed model repeated measures analyses with group and time
as fixed factors and animal as a random factor. Post-hoc tests corresponding to preplanned comparisons were based on linear contrasts comparing changes from baseline
to post-injection days 3 and 6 between groups for both sexes. Statistical significance was
determined based on p < 0.05. Analyses were performed using SAS Statistical Software
Version 9.4 (SAS Institute, Cary, NC, USA).
The Wald test was used to generate p-values and log2 fold changes for expressed
genes quantified by RNA-Seq. Significantly differentially expressed genes quantified by
RNA-Seq were identified if the p-value was <0.05 and upregulation was greater than 2.3
or downregulation greater than 0.5 on a log2 fold change scale. Three analysis groups
were pooled for gene expression identification: Female PBS vs. Female rhPRG4; Male
PBS vs. Male rhPRG4; and Both sexes PBS vs. rhPRG4. R studio (Boston, MA, USA) was
used to create heatmaps using the “pheatmap” package. GraphPad Prism (San Diego, CA,
USA) was used to illustrate log2 fold changes in differential genes, log10 fold changes in
fluorescence intensity, and statistical differences in the numbers of activated caspase-3positive chondrocytes between PBS- and rhPRG4-injected joints. A Volcano plot of log10
of the adjusted p-value against the log2 fold change in differentially expressed genes was
constructed in the R open source statistical computing software.

Int. J. Mol. Sci. 2022, 23, 4245

16 of 19

Supplementary Materials: The following supporting information can be downloaded at: https:
//www.mdpi.com/article/10.3390/ijms23084245/s1.
Author Contributions: Conceptualization, G.D.J. and K.A.E.; Methodology, D.S.Y. and G.J.B.; Software, D.S.Y. and E.E.D.; Validation, L.X.Z. and E.E.D.; Formal Analysis, G.D.J., K.A.E., H.R., P.N.K.,
A.M.F. and G.J.B.; Investigation, G.D.J., P.N.K. and K.A.E.; Resources, G.D.J. and T.A.S.; Data Curation, D.S.Y. and G.J.B.; Writing—Original Draft Preparation, D.S.Y. and G.D.J.; Writing—Review
and Editing, D.S.Y., E.E.D., L.X.Z., H.R., P.N.K., G.J.B., T.A.S., A.M.F., K.A.E. and G.D.J.; Project
Administration, L.X.Z.; Funding Acquisition, G.D.J. and K.A.E. All authors have read and agreed to
the published version of the manuscript.
Funding: This work was supported by the NIH grant R01AR067748 from NIAMS to K.A.E. and G.D.J.
Institutional Review Board Statement: All animal experiments were approved by the Rhode Island
Hospital Animal Welfare Committee under reference #019912.
Informed Consent Statement: Not applicable.
Data Availability Statement: Data is publicly available on Zenodo site which can be accessed
through https://doi.org/10.5281/zenodo.6426032 (accessed on 30 March 2022).
Acknowledgments: The authors wish to thank Sandra Spaziano in the editing and submission of
the manuscript.
Conflicts of Interest: Author G.J. authored patents on rhPRG4 and holds equity in Lubris LLC, MA,
USA. Author T.S. authored patents on rhPRG4, is a paid consultant for Lubris LLC, MA, USA and
holds equity in Lubris LLC, MA, USA.

References
1.
2.

3.
4.

5.

6.

7.
8.
9.
10.

11.

12.
13.

Schaefer, D.B.; Wendt, D.; Moretti, M.; Jakob, M.; Jay, G.D.; Heberer, M.; Martin, I. Lubricin reduces cartilage—Cartilage
integration. Biorheology 2004, 41, 503–508.
Rhee, D.K.; Marcelino, J.; Al-Mayouf, S.; Schelling, D.K.; Bartels, C.F.; Cui, Y.; Laxer, R.; Goldbach-Mansky, R.; Warman, M.L.
Consequences of Disease-causing Mutations on Lubricin Protein Synthesis, Secretion, and Post-translational Processing. J. Biol.
Chem. 2005, 280, 31325–31332. [CrossRef]
Hill, A.; Waller, K.A.; Cui, Y.; Allen, J.M.; Smits, P.; Zhang, L.X.; Ayturk, U.M.; Hann, S.; Lessard, S.G.; Zurakowski, D.; et al.
Lubricin restoration in a mouse model of congenital deficiency. Arthritis Rheumatol. 2015, 67, 3070–3081. [CrossRef]
Yilmaz, S.; Uludag Alkaya, D.; Kasapcopur, O.; Barut, K.; Akdemir, E.S.; Celen, C.; Youngblood, M.W.; Yasuno, K.; Bilguvar, K.;
Gunel, M.; et al. Genotype-phenotype investigation of 35 patients from 11 unrelated families with camptodactyly-arthropathycoxa vara-pericarditis (CACP) syndrome. Mol. Genet. Genom. Med. 2018, 6, 230–248. [CrossRef]
Waller, K.A.; Chin, K.E.; Jay, G.D.; Zhang, L.X.; Teeple, E.; McAllister, S.; Badger, G.J.; Schmidt, T.A.; Fleming, B.C. Intra-articular
Recombinant Human Proteoglycan 4 Mitigates Cartilage Damage After Destabilization of the Medial Meniscus in the Yucatan
Minipig. Am. J. Sports Med. 2017, 45, 1512–1521. [CrossRef]
Rhee, D.K.; Marcelino, J.; Baker, M.; Gong, Y.; Smits, P.; Lefebvre, V.; Jay, G.D.; Stewart, M.; Wang, H.; Warman, M.L.; et al. The
secreted glycoprotein lubricin protects cartilage surfaces and inhibits synovial cell overgrowth. J. Clin. Investig. 2005, 115, 622–631.
[CrossRef]
Jay, G.D.; Torres, J.R.; Rhee, D.K.; Helminen, H.J.; Hytinnen, M.M.; Cha, C.J.; Elsaid, K.; Kim, K.S.; Cui, Y.; Warman, M.L.
Association between friction and wear in diarthrodial joints lacking lubricin. Arthritis Rheum. 2007, 56, 3662–3669. [CrossRef]
Waller, K.A.; Zhang, L.X.; Jay, G.D. Friction-Induced Mitochondrial Dysregulation Contributes to Joint Deterioration in Prg4
Knockout Mice. Int. J. Mol. Sci. 2017, 18, 1252. [CrossRef]
Waller, K.A.; Zhang, L.X.; Elsaid, K.A.; Fleming, B.C.; Warman, M.L.; Jay, G.D. Role of lubricin and boundary lubrication in the
prevention of chondrocyte apoptosis. Proc. Natl. Acad. Sci. USA 2013, 110, 5852–5857. [CrossRef]
Bahabri, S.A.; Suwairi, W.M.; Laxer, R.M.; Polinkovsky, A.; Dalaan, A.A.; Warman, M.L. The camptodactyly-arthropathy-coxa
vara-pericarditis syndrome: Clinical features and genetic mapping to human chromosome 1. Arthritis Rheum. 1998, 41, 730–735.
[CrossRef]
Marcelino, J.; Carpten, J.D.; Suwairi, W.M.; Gutierrez, O.M.; Schwartz, S.; Robbins, C.; Sood, R.; Makalowska, I.; Baxevanis, A.;
Johnstone, B.; et al. CACP, encoding a secreted proteoglycan, is mutated in camptodactyly-arthropathy-coxa vara-pericarditis
syndrome. Nat. Genet. 1999, 23, 319–322. [CrossRef]
Bao, J.-P.; Chen, W.-P.; Wu, L.-D. Lubricin: A novel potential biotherapeutic approaches for the treatment of osteoarthritis. Mol.
Biol. Rep. 2010, 38, 2879–2885. [CrossRef]
Alazami, A.M.; Al-Mayouf, S.M.; Wyngaard, C.-A.; Meyer, B. Novel PRG4 mutations underlie CACP in Saudi families. Hum.
Mutat. 2006, 27, 213. [CrossRef]

Int. J. Mol. Sci. 2022, 23, 4245

14.
15.
16.
17.

18.

19.

20.
21.
22.
23.

24.

25.
26.
27.
28.
29.

30.
31.

32.
33.
34.
35.
36.
37.
38.

17 of 19

Al-Mayouf, S.M.; Albuhairan, I. Camptodactyly-arthropathy-coxa vara-pericarditis syndrome: Clinical and molecular genetic
findings. Bone Abstr. 2013, 2, 5.
Drewniak, E.I.; Jay, G.D.; Fleming, B.C.; Zhang, L.; Warman, M.L.; Crisco, J.J. Cyclic loading increases friction and changes
cartilage surface integrity in lubricin-mutant mouse knees. Arthritis Rheum. 2012, 64, 465–473. [CrossRef]
Bonnevie, E.D.; Delco, M.L.; Bartell, L.R.; Jasty, N.; Cohen, I.; Fortier, L.A.; Bonassar, L.J. Microscale frictional strains determine
chondrocyte fate in loaded cartilage. J. Biomech. 2018, 74, 72–78. [CrossRef]
Ludwig, T.E.; McAllister, J.R.; Lun, V.; Wiley, J.P.; Schmidt, T.A. Diminished cartilage-lubricating ability of human osteoarthritic
synovial fluid deficient in proteoglycan 4: Restoration through proteoglycan 4 supplementation. Arthritis Rheum. 2012, 64,
3963–3971. [CrossRef]
Jay, G.D.; Elsaid, K.A.; Kelly, K.A.; Anderson, S.C.; Zhang, L.; Teeple, E.; Waller, K.; Fleming, B.C. Prevention of cartilage
degeneration and gait asymmetry by lubricin tribosupplementation in the rat following anterior cruciate ligament transection.
Arthritis Rheum. 2012, 64, 1162–1171. [CrossRef]
Emad, Y.; Ragab, Y.; Khalifa, M.; Bassyouni, I.; EL-Shaarawy, N.; Rasker, J.J. Axial involvement with facet joint arthropathy and
bony ankylosis in a case of camptodactyly, arthropathy, coxa vara, pericarditis (CACP) syndrome. Jt. Bone Spine 2013, 80, 520–522.
[CrossRef]
Jacobs, B.Y.; Kloefkorn, H.E.; Allen, K.D. Gait Analysis Methods for Rodent Models of Osteoarthritis. Curr. Pain Headache Rep.
2014, 18, 456. [CrossRef]
Zitnay, J.L.; Li, Y.; Qin, Z.; San, B.H.; Depalle, B.; Reese, S.P.; Buehler, M.J.; Yu, S.M.; Weiss, J.A. Molecular level detection and
localization of mechanical damage in collagen enabled by collagen hybridizing peptides. Nat. Commun. 2017, 8, 14913. [CrossRef]
Waters, J.C. Accuracy and precision in quantitative fluorescence microscopy. J. Cell Biol. 2009, 185, 1135–1148. [CrossRef]
Jay, G.D.; Tantravahi, U.; Britt, D.E.; Barrach, H.J.; Cha, C.-J. Homology of lubricin and superficial zone protein (SZP): Products of
megakaryocyte stimulating factor (MSF) gene expression by human synovial fibroblasts and articular chondrocytes localized to
chromosome 1q25. J. Orthop. Res. 2001, 19, 677–687. [CrossRef]
Flannery, C.R.; Hughes, C.E.; Schumacher, B.L.; Tudor, D.; Aydelotte, M.B.; Kuettner, K.E.; Caterson, B. Articular cartilage
superficial zone protein (SZP) is homologous to megakaryocyte stimulating factor precursor and Is a multifunctional proteoglycan
with potential growth-promoting, cytoprotective, and lubricating properties in cartilage metabolism. Biochem. Biophys. Res.
Commun. 1999, 254, 535–541. [CrossRef]
Albuhairan, I.; Al-Mayouf, S.M. Camptodactyly-arthropathy-coxavara-pericarditis syndrome in Saudi Arabia: Clinical and
molecular genetic findings in 22 patients. Semin. Arthritis Rheum. 2013, 43, 292–296. [CrossRef]
D’Lima, D.; Hermida, J.; Hashimoto, S.; Colwell, C.; Lotz, M. Caspase inhibitors reduce severity of cartilage lesions in experimental
osteoarthritis. Arthritis Rheum. 2006, 54, 1814–1821. [CrossRef]
Bartell, L.R.; Fortier, L.A.; Bonassar, L.J.; Szeto, H.H.; Cohen, I.; Delco, M.L. Mitoprotective therapy prevents rapid, straindependent mitochondrial dysfunction after articular cartilage injury. J. Orthop. Res. 2020, 38, 1257–1267. [CrossRef]
Wahyudi, H.; Reynolds, A.A.; Li, Y.; Owen, S.C.; Yu, S.M. Targeting collagen for diagnostic imaging and therapeutic delivery. J.
Control. Release 2016, 240, 323–331. [CrossRef]
Majd, S.E.; Kuijer, R.; Kowitsch, A.; Groth, T.; Schmidt, T.A.; Sharma, P.K. Both hyaluronan and collagen type II keep proteoglycan
4 (lubricin) at the cartilage surface in a condition that provides low friction during boundary lubrication. Langmuir 2014, 30,
14566–14572. [CrossRef]
Chappuis, J.; Sherman, I.A.; Neumann, A.W. Surface tension of animal cartilage as it relates to friction in joints. Ann. Biomed. Eng.
1983, 11, 435–449. [CrossRef]
Schlapakow, E.; Peeva, V.; Zsurka, G.; Jeub, M.; Wabbels, B.; Kornblum, C.; Kunz, W.S. Distinct segregation of the pathogenic
m.5667G>A mitochondrial tRNA(Asn) mutation in extraocular and skeletal muscle in chronic progressive external ophthalmoplegia. Neuromuscul. Disord. 2019, 29, 358–367. [CrossRef]
Reyes, A.; He, J.; Mao, C.C.; Bailey, L.J.; Di Re, M.; Sembongi, H.; Kazak, L.; Dzionek, K.; Holmes, J.B.; Cluett, T.J.; et al. Actin and
myosin contribute to mammalian mitochondrial DNA maintenance. Nucleic Acids Res. 2011, 39, 5098–5108. [CrossRef]
Johnston, J.R.; Chase, P.B.; Pinto, J.R. Troponin through the looking-glass: Emerging roles beyond regulation of striated muscle
contraction. Oncotarget 2018, 9, 1461–1482. [CrossRef]
GeneCards.TNNI1-TroponinI1, Slow Skeletal Type. Available online: https://www.genecards.org/cgi-bin/carddisppl?gene=
TNNI1&keywords=Tnni1 (accessed on 30 March 2022).
Franz, M.; Rodriguez, H.; Lopes, C.; Zuberi, K.; Montojo, J.; Bader, G.D.; Morris, Q. GeneMANIA update 2018. Nucleic Acids Res.
2018, 46, W60–W64. [CrossRef]
Wang, Q.; Lin, J.L.; Erives, A.J.; Lin, C.I.; Lin, J.J. New insights into the roles of Xin repeat-containing proteins in cardiac
development, function, and disease. Int. Rev. Cell Mol. Biol. 2014, 310, 89–128.
Maurya, S.K.; Herrera, J.L.; Sahoo, S.K.; Reis, F.C.G.; Vega, R.B.; Kelly, D.P.; Periasamy, M. Sarcolipin Signaling Promotes
Mitochondrial Biogenesis and Oxidative Metabolism in Skeletal Muscle. Cell Rep. 2018, 24, 2919–2931. [CrossRef]
Bean, C.; Verma, N.K.; Yamamoto, D.L.; Chemello, F.; Cenni, V.; Filomena, M.C.; Chen, J.; Bang, M.L.; Lanfranchi, G. Ankrd2 is a
modulator of NF-κB-mediated inflammatory responses during muscle differentiation. Cell Death Dis. 2014, 5, e1002. [CrossRef]

Int. J. Mol. Sci. 2022, 23, 4245

39.

40.

41.

42.
43.

44.
45.
46.
47.

48.

49.
50.
51.
52.
53.

54.
55.

56.
57.
58.
59.

60.
61.

62.

18 of 19

Park, N.; Marquez, J.; Garcia, M.V.F.; Shimizu, I.; Lee, S.R.; Kim, H.K.; Han, J. Phosphorylation in Novel Mitochondrial Creatine
Kinase Tyrosine Residues Render Cardioprotection against Hypoxia/Reoxygenation Injury. J. Lipid Atheroscler. 2021, 10, 223–239.
[CrossRef]
Niemann, A.; Huber, N.; Wagner, K.M.; Somandin, C.; Horn, M.; Lebrun-Julien, F.; Angst, B.; Pereira, J.A.; Halfter, H.;
Welzl, H.; et al. The Gdap1 knockout mouse mechanistically links redox control to Charcot–Marie–Tooth disease. Brain 2014, 137,
668–682. [CrossRef]
Chen, W.; Li, N.; Chen, T.; Han, Y.; Li, C.; Wang, Y.; He, W.; Zhang, L.; Wan, T.; Cao, X. The lysosome-associated apoptosis-inducing
protein containing the pleckstrin homology (PH) and FYVE domains (LAPF), representative of a novel family of PH and FYVE
domain-containing proteins, induces caspase-independent apoptosis via the lysosomal-mitochondrial pathway. J. Biol. Chem.
2005, 280, 40985–40995.
Tiosano, D.; Mears, J.A.; Buchner, D.A. Mitochondrial Dysfunction in Primary Ovarian Insufficiency. Endocrinology 2019, 160,
2353–2366. [CrossRef] [PubMed]
Plaas, A.; Li, J.; Riesco, J.; Das, R.; Sandy, J.D.; Harrison, A. Intraarticular injection of hyaluronan prevents cartilage erosion,
periarticular fibrosis and mechanical allodynia and normalizes stance time in murine knee osteoarthritis. Arthritis Res. Ther. 2011,
13, R46. [CrossRef] [PubMed]
Vincelette, J.; Xu, Y.; Zhang, L.-N.; Schaefer, C.J.; Vergona, R.; Sullivan, M.E.; Hampton, T.G.; Wang, Y.-X. Gait analysis in a murine
model of collagen-induced arthritis. Arthritis Res. Ther. 2007, 9, R123. [CrossRef] [PubMed]
Feldman, G.; Offemaria, A.; Sawan, H.; Parvizi, J.; Freeman, T.A. A murine model for developmental dysplasia of the hip:
Ablation of CX3CR1 affects acetabular morphology and gait. J. Transl. Med. 2017, 15, 233. [CrossRef] [PubMed]
Berryman, E.R.; Harris, R.L.; Moalli, M.; Bagi, C.M. Digigait quantitation of gait dynamics in rat rheumatoid arthritis model. J.
Musculoskelet. Neuronal Interact. 2009, 9, 89–98.
Elsaid, K.A.; Zhang, L.; Waller, K.; Tofte, J.; Teeple, E.; Fleming, B.C.; Jay, G.D. The impact of forced joint exercise on lubricin
biosynthesis from articular cartilage following ACL transection and intra-articular lubricin’s effect in exercised joints following
ACL transection. Osteoarthr. Cartil. 2012, 20, 940–948. [CrossRef]
Qadri, M.; Jay, G.D.; Zhang, L.X.; Wong, W.; Reginato, A.M.; Sun, C.; Schmidt, T.A.; Elsaid, K.A. Recombinant human proteoglycan4 reduces phagocytosis of urate crystals and downstream nuclear factor kappa B and inflammasome activation and production of
cytokines and chemokines in human and murine macrophages. Arthritis Res. Ther. 2018, 20, 192. [CrossRef]
Malfait, A.M.; Miller, R.E. Why we should study osteoarthritis pain in experimental models in both sexes. Osteoarthr. Cartil. 2020,
28, 397–399. [CrossRef]
Ma, H.-L.; Blanchet, T.J.; Peluso, D.; Hopkins, B.; Morris, E.A.; Glasson, S.S. Osteoarthritis severity is sex dependent in a surgical
mouse model. Osteoarthr. Cartil. 2007, 15, 695–700. [CrossRef]
Griffin, T.M.; Scanzello, C.R. Innate inflammation and synovial macrophages in osteoarthritis pathophysiology. Clin. Exp.
Rheumatol. 2019, 37 (Suppl. 120), 57–63.
Miller, R.J.; Malfait, A.-M.; Miller, R.E. The innate immune response as a mediator of osteoarthritis pain. Osteoarthr. Cartil. 2020,
28, 562–571. [CrossRef] [PubMed]
Sorge, R.E.; Mapplebeck, J.C.S.; Rosen, S.; Beggs, S.; Taves, S.; Alexander, J.K.; Martin, L.J.; Austin, J.-S.; Sotocinal, S.G.; Chen,
D.; et al. Different immune cells mediate mechanical pain hypersensitivity in male and female mice. Nat. Neurosci. 2015, 18,
1081–1083. [CrossRef] [PubMed]
Miller, R.E.; Ishihara, S.; Tran, P.B.; Golub, S.B.; Last, K.; Miller, R.J.; Fosang, A.J.; Malfait, A.M. An aggrecan fragment drives
osteoarthritis pain through Toll-like receptor 2. JCI Insight 2018, 3, e95704. [CrossRef] [PubMed]
Alquraini, A.; Garguilo, S.; D’Souza, G.; Zhang, L.X.; Schmidt, T.A.; Jay, G.D.; Elsaid, K.A. The interaction of lubricin/proteoglycan
4 (PRG4) with toll-like receptors 2 and 4: An anti-inflammatory role of PRG4 in synovial fluid. Arthritis Res. Ther. 2015, 17, 353.
[CrossRef]
Iqbal, S.M.; Leonard, C.; Regmi, S.C.; De Rantere, D.; Tailor, P.; Ren, G.; Ishida, H.; Hsu, C.; Abubacker, S.; Pang, D.S.; et al.
Lubricin/Proteoglycan 4 binds to and regulates the activity of Toll-Like Receptors In Vitro. Sci. Rep. 2016, 6, 18910. [CrossRef]
Qadri, M.; Jay, G.D.; Zhang, L.X.; Schmidt, T.A.; Totonchy, J.; Elsaid, K.A. Proteoglycan-4 is an essential regulator of synovial
macrophage polarization and inflammatory macrophage joint infiltration. Arthritis Res. Ther. 2021, 23, 241. [CrossRef]
Tang, H.M.; Tang, H.L. Anastasis: Recovery from the brink of cell death. R. Soc. Open Sci. 2018, 5, 180442. [CrossRef]
Liu, J.; Zhang, D.; Mi, X.; Xia, Q.; Yu, Y.; Zuo, Z.; Guo, W.; Zhao, X.; Cao, J.; Yang, Q.; et al. p27 suppresses arsenite-induced
Hsp27/Hsp70 expression through inhibiting JNK2/c-Jun- and HSF-1-dependent pathways. J. Biol. Chem. 2010, 285, 26058–26065.
[CrossRef]
Hwang, H.S.; Kim, H.A. Chondrocyte Apoptosis in the Pathogenesis of Osteoarthritis. Int. J. Mol. Sci. 2015, 16, 26035–26054.
[CrossRef]
Lee, S.W.; Lee, H.J.; Chung, W.T.; Choi, S.M.; Rhyu, S.H.; Kim, D.K.; Kim, K.T.; Kim, J.Y.; Kim, J.-M.; Yoo, Y.H. TRAIL induces
apoptosis of chondrocytes and influences the pathogenesis of experimentally induced rat osteoarthritis. Arthritis Rheum. 2004, 50,
534–542. [CrossRef]
Pettersen, I.; Figenschau, Y.; Olsen, E.; Bakkelund, W.; Smedsrod, B.; Sveinbjornsson, B. Tumor necrosis factor-related apoptosisinducing ligand induces apoptosis in human articular chondrocytes in vitro. Biochem. Biophys. Res. Commun. 2002, 296, 671–676.
[CrossRef]

Int. J. Mol. Sci. 2022, 23, 4245

63.

64.

65.
66.
67.
68.
69.

70.
71.

72.
73.
74.

75.

76.
77.
78.

79.

80.
81.
82.
83.
84.
85.
86.
87.

19 of 19

Ruiz-Romero, C.; Calamia, V.; Mateos, J.; Carreira, V.; Martinez-Gomariz, M.; Fernandez, M.; Blanco, F.J. Mitochondrial
dysregulation of osteoarthritic human articular chondrocytes analyzed by proteomics: A decrease in mitochondrial superoxide
dismutase points to a redox imbalance. Mol. Cell. Proteom. MCP 2009, 8, 172–189. [CrossRef]
Al-Sharif, A.; Jamal, M.; Zhang, L.X.; Larson, K.; Schmidt, T.A.; Jay, G.; Elsaid, K.A. Lubricin/Proteoglycan 4 Binding to CD44
Receptor: A Mechanism of the Suppression of Proinflammatory Cytokine-Induced Synoviocyte Proliferation by Lubricin. Arthritis
Rheumatol. 2015, 67, 1503–1513. [CrossRef] [PubMed]
Del Carlo, M., Jr.; Loeser, R.F. Nitric oxide-mediated chondrocyte cell death requires the generation of additional reactive oxygen
species. Arthritis Rheum. 2002, 46, 394–403. [CrossRef]
Kühn, K.; D’Lima, D.; Hashimoto, S.; Lotz, M. Cell death in cartilage. Osteoarthr. Cartil. 2004, 12, 1–16. [CrossRef]
Higuchi, M.; Honda, T.; Proske, R.J.; Yeh, E.T. Regulation of reactive oxygen species-induced apoptosis and necrosis by caspase
3-like proteases. Oncogene 1998, 17, 2753–2760. [CrossRef]
Larson, K.M.; Zhang, L.; Badger, G.J.; Jay, G.D. Early genetic restoration of lubricin expression in transgenic mice mitigates
chondrocyte peroxynitrite release and caspase-3 activation. Osteoarthr. Cartil. 2017, 25, 1488–1495. [CrossRef]
Grishko, V.; Xu, M.; Ho, R.; Mates, A.; Watson, S.; Kim, J.T.; Wilson, G.L.; Pearsall, A.W. Effects of hyaluronic acid on mitochondrial
function and mitochondria-driven apoptosis following oxidative stress in human chondrocytes. J. Biol. Chem. 2009, 284, 9132–9139.
[CrossRef]
Blanco, F.J.; Rego, I.; Ruiz-Romero, C. The role of mitochondria in osteoarthritis. Nat. Rev. Rheumatol. 2011, 7, 161–169. [CrossRef]
Matsuzaki, T.; Alvarez-Garcia, O.; Mokuda, S.; Nagira, K.; Olmer, M.; Gamini, R.; Miyata, K.; Akasaki, Y.; Su, A.I.;
Asahara, H.; et al. FoxO transcription factors modulate autophagy and proteoglycan 4 in cartilage homeostasis and osteoarthritis.
Sci. Transl. Med. 2018, 10, eaan0746. [CrossRef]
Akula, S.K.; McCullough, K.B.; Weichselbaum, C.; Dougherty, J.D.; Maloney, S.E. The trajectory of gait development in mice.
Brain Behav. 2020, 10, e01636. [CrossRef] [PubMed]
Dorman, C.W.; Krug, H.E.; Frizelle, S.P.; Funkenbusch, S.; Mahowald, M.L. A comparison of DigiGait and TreadScan imaging
systems: Assessment of pain using gait analysis in murine monoarthritis. J. Pain Res. 2013, 7, 25–35. [CrossRef] [PubMed]
Hurtig, M.; Zaghoul, I.; Sheardown, H.; Schmidt, T.A.; Liu, L.; Zhang, L.; Elsaid, K.A.; Jay, G.D. Two compartment pharmacokinetic
model describes the intra-articular delivery and retention of rhprg4 following ACL transection in the Yucatan mini pig. J. Orthop.
Res. 2019, 37, 386–396. [CrossRef] [PubMed]
Ai, M.; Cui, Y.; Sy, M.S.; Lee, D.M.; Zhang, L.X.; Larson, K.M.; Kurek, K.C.; Jay, G.D.; Warman, M.L. Anti-lubricin monoclonal
antibodies created using lubricin-knockout mice immunodetect lubricin in several species and in patients with healthy and
diseased joints. PLoS ONE 2015, 10, e0116237. [CrossRef]
Mao, X.; Fu, P.; Wang, L.; Xiang, C. Mitochondria: Potential Targets for Osteoarthritis. Front. Med. 2020, 7, 581402. [CrossRef]
[PubMed]
Ruan, M.Z.; Erez, A.; Guse, K.; Dawson, B.; Bertin, T.; Chen, Y.; Jiang, M.M.; Yustein, J.; Gannon, F.; Lee, B.H. Proteoglycan 4
expression protects against the development of osteoarthritis. Sci. Transl. Med. 2013, 5, 176ra134. [CrossRef]
Seol, D.; Choe, H.H.; Zheng, H.; Brouillette, M.J.; Fredericks, D.C.; Petersen, E.B.; Song, I.; Jaidev, L.R.; Salem, A.; Martin, J.A.
Intra-Articular Adeno-Associated Virus-Mediated Proteoglycan 4 Gene Therapy for Preventing Post-Traumatic Osteoarthritis.
Hum. Gene Ther. 2022. [CrossRef]
Lambiase, A.; Sullivan, B.D.; Schmidt, T.A.; Sullivan, D.A.; Jay, G.D.; Truitt, E.R., 3rd; Bruscolini, A.; Sacchetti, M.; Mantelli, F. A
Two-Week, Randomized, Double-masked Study to Evaluate Safety and Efficacy of Lubricin (150 mug/mL) Eye Drops Versus
Sodium Hyaluronate (HA) 0.18% Eye Drops (Vismed(R)) in Patients with Moderate Dry Eye Disease. Ocul. Surf. 2017, 15, 77–87.
[CrossRef]
Abubacker, S.; Dorosz, S.G.; Ponjevic, D.; Jay, G.; Matyas, J.R.; Schmidt, T.A. Full-Length Recombinant Human Proteoglycan 4
Interacts with Hyaluronan to Provide Cartilage Boundary Lubrication. Ann. Biomed. Eng. 2016, 44, 1128–1137. [CrossRef]
Samsom, M.L.; Morrison, S.; Masala, N.; Sullivan, B.D.; Sullivan, D.A.; Sheardown, H.; Schmidt, T.A. Characterization of
full-length recombinant human Proteoglycan 4 as an ocular surface boundary lubricant. Exp. Eye Res. 2014, 127, 14–19. [CrossRef]
Xu, Y.; Tian, N.X.; Bai, Q.-Y.; Chen, Q.; Sun, X.-H.; Wang, Y. Gait Assessment of Pain and Analgesics: Comparison of the DigiGait
and CatWalk Gait Imaging Systems. Neurosci. Bull. 2019, 35, 401–418. [CrossRef] [PubMed]
Hwang, J.; Huang, Y.; Burwell, T.J.; Peterson, N.C.; Connor, J.; Weiss, S.J.; Yu, S.M.; Li, Y. In Situ Imaging of Tissue Remodeling
with Collagen Hybridizing Peptides. ACS Nano 2017, 11, 9825–9835. [CrossRef] [PubMed]
Qadri, M.; Jay, G.D.; Zhang, L.X.; Richendrfer, H.; Schmidt, T.A.; Elsaid, K.A. Proteoglycan-4 regulates fibroblast to myofibro-blast
transition and expression of fibrotic genes in the synovium. Arthritis Res. 2020, 22, 113. [CrossRef]
Livak, K.J.; Schmittgen, T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta
C(T)) Method. Methods 2001, 25, 402–408. [CrossRef] [PubMed]
Zhou, Y.; Liu, D.; Kaminski, H.J. Myosin Heavy Chain Expression in Mouse Extraocular Muscle: More Complex than Expected.
Investig. Opthalmology Vis. Sci. 2010, 51, 6355–6363. [CrossRef] [PubMed]
Greene, G.W.; Martin, L.; Tabor, R.; Michalczyk, A.; Ackland, L.; Horn, R. Lubricin: A versatile, biological anti-adhesive with
properties comparable to polyethylene glycol. Biomaterials 2015, 53, 127–136. [CrossRef] [PubMed]

